We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Influence of HER2 expression on prognosis in metastatic triple-negative breast cancer-results from an international, multicenter analysis coordinated by the AGMT Study Group
ESMO Open 2023 Feb 01;8(1)100747, SP Gampenrieder, V Dezentjé, M Lambertini, A de Nonneville, M Marhold, F Le Du, A Cortés Salgado, D Alpuim Costa, M Vaz Batista, N Chic Ruché, C Tinchon, A Petzer, E Blondeaux, L Del Mastro, G Targato, F Bertucci, A Gonçalves, F Viret, R Bartsch, C Mannsbart, A Deleuze, L Robert, C Saavedra Serrano, M Gion Cortés, M Sampaio-Alves, M Vitorino, L Pecen, C Singer, N Harbeck, G Rinnerthaler, R Greil